Cannabinoids

The Noramco Difference

Pharmaceutical companies trust Noramco to produce ultra-pure synthetic cannabinoid active ingredients that meet the strictest regulatory requirements of health authorities around the world. High capacity cGMP production facilities in Europe and the United States yield ultra-pure Cannabidiol (CBD), Dronabinol (THC), and Nabilone active ingredients.

Addiction Treatment

For more than a decade Noramco has consistently delivered large volumes of Nal-family compounds and Buprenorphine HCI to the pharmaceutical industry. Noramco has made a long-term commitment to antagonist APIs, providing both the technologies and expertise pharmaceutical companies require to produce and commercialize addiction treatment and abuse prevention products (ATAP).

Latest News

The latest news and updates from Noramco.

Say Hello to Nancy Bye

Supporting the Senior Leadership Team at Noramco, Nancy Bye keeps everyone on track. That can be a tall order in a busy corporate headquarters. But working for the company since 2010, she knows what to do and who to call to make everything run like clockwork.

Noramco at AAPS 2018

Noramco is participating in the Scientific Thought Leadership program at this year’s AAPS. Dr. Wen-Chun Zhang will be presenting a Chalk Talk on the topic of “The New Era of Ultra-Pure Synthetic Cannabinoids” on Tuesday, November 6th, 2018 from 10:30 am to 10:50.

ADHD API Portfolio

Building out our ADHD capability for customers that want to work with us strategically throughout the ADHD range of technology, Noramco now offers a full range of APIs. ADHD focus products, an area which leverages our controlled substance expertise, and over a decade of supply, is an increasingly important technology platform within Noramco. Customers may call on us for high-quality Methylphenidate HCl, DexMethylphenidate, and Amphetamine Salts.